The algorithm of treatment of the patient with relapsing-remitting multiple sclerosis with suboptimal response:the example of a clinical case
https://doi.org/10.21518/2079-701X-2018-9-46-49
Abstract
This article presents a clinical case of suboptimal response to multiple sclerosis therapy and an algorithm for treatment, taking into account the existing performance criteria.
About the Authors
E. V. Popova
Interregional Department of Multiple Sclerosis at Moscow Clinical Hospital №24; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
V. V. Bryukhov
Research Center of Neurology
Russian Federation
Russian Federation
Moscow
A. N. Boyko
Interregional Department of Multiple Sclerosis at Moscow Clinical Hospital №24; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
M. V. Krotenkova
Research Center of Neurology
Russian Federation
Russian Federation
Moscow
References
1. Lublin FD et al. Defining the clinical course of multiple sclerosis, The 2013 revisions. Neurology, 2014 Jul 15,). 83(3): 278–286. doi:10.1212/WNL.0000000000000560.
2. Freedman M, Rush C Severe, Highly Active, or Aggressive Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology, 2016, 22: 761784. doi: 10.1212/con.0000000000000331.
3. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology, 69(2): 292-302. doi:10.1002/ana.22366.
4. Alifirova VM, Boyko AN, Vlasov YaV, et al. Clinical guidelines for use of dimethyl fumarate in remitting-relapsing multiple sclerosis. Zhurn. Nevrol i Psikhiatr, 2017, 1: 97-102. doi: 10/17116/jnevro20171171197-102
5. Moharregh-Khiabani D, Linker R, Gold R, Stangel M. Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis. Current Neuropharmacology, 2009, 7(1): 60-64. doi:10.2174/157015909787602788.
6. Sormani MP, Rio J, Tintore M, Signori A, Li D, Cornelisse P. Scoring treatment response in patients with relapsing multiplesclerosis. Mult Scler, 2013, 19: 605-612. doi:10.1177/1352458512460605.
7. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J NeurolSci, 2013, 40: 307-323. doi: 10.1017/S0317167100014244.
8. Criteria for ineffectiveness of therapy and cancellation of multiple sclerosis disease modifying drugs of the first line and replacement them for second-line therapy. Zhurnal Nevrologii i Psikhiatrii Im. S.S. Korsakova. Prilozheniye, 2015, 115 (8): 44-44. doi: 10.17116/jnevro20151158244.
9. Inc. M. Longer-term follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE. Onlinelibraryectrims-congresseu. 2016. Available at: http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115560/. Accessed April 24, 2016.
10. Viglietta V, Miller D, Bar-Or A et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology, 2014, 2(2): 103118. doi:10.1002/acn3.148.
Review
For citations:
Popova EV, Bryukhov VV, Boyko AN, Krotenkova MV. The algorithm of treatment of the patient with relapsing-remitting multiple sclerosis with suboptimal response:the example of a clinical case. Meditsinskiy sovet = Medical Council. 2018;(9):46-49. (In Russ.) https://doi.org/10.21518/2079-701X-2018-9-46-49
Views:
713
Email this article 